

Special Issue

Natural Products in Photodynamic Therapy, 2nd Edition

Message from the Guest Editors

More than a century ago, scientists discovered that when light is combined with specific chemicals, it can cause the death of cells. Acridine, eosin, and haematoporphyrin were the first natural products employed as photosensitizers (PS) in photodynamic therapy (PDT). From 1999 onwards, first- and second-generation PS, like porphyrin, chlorin, and cyanine, and other dyes, such as methylene blue, toluidine blue, rose bengal, and hypericin, have been used in the design of drugs for use in PDT, with some of these being approved by the FDA. Despite increasing amounts of research in the last decade focusing on PDT and its effects and applications, to date, less attention has been paid to plant extracts or molecules of natural origin and the study of their phototoxic activity. In this Special Issue, we aim to receive original research articles and review articles regarding the use of natural products as PS and/or as bioactive compounds in association with photodynamic therapy for application as combination therapy.

Guest Editors

Dr. Renato Sonchini Gonçalves

Department of Chemistry, Laboratory of Chemistry of Natural Products,
Federal University of Maranhão, São Luís 65080-805, Brazil

Prof. Dr. Gustavo Braga

Department of Chemistry, Federal University of Maranhão, São Luís
65080-805, Brazil

Deadline for manuscript submissions

20 July 2026



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/262966

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).